Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$56.66 USD
-2.41 (-4.08%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $55.92 -0.74 (-1.31%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/13/24 |
---|---|
Current Quarter | -1.16 |
EPS Last Quarter | -0.83 |
Last EPS Surprise | 23.85% |
ABR | 1.17 |
Earnings ESP
|
10.78% |
---|---|
Current Year | -4.68 |
Next Year | -4.47 |
EPS (TTM) | -6.96 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -1.16 | -1.30 | -4.68 | -4.47 |
# of Estimates | 5 | 5 | 5 | 5 |
Most Recent Consensus | -0.80 | -0.84 | -3.20 | -2.47 |
High Estimate | -0.80 | -0.84 | -3.20 | -2.47 |
Low Estimate | -1.71 | -2.06 | -6.99 | -6.47 |
Year ago EPS | -2.05 | -2.27 | -10.31 | -4.68 |
Year over Year Growth Est. | 43.41% | 42.73% | 54.61% | 4.44% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 0 | 0 | 0 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -1.16 | -1.30 | -4.68 | -4.47 |
7 Days Ago | -1.25 | -1.42 | -5.05 | -4.97 |
30 Days Ago | -1.24 | -1.45 | -5.11 | -5.18 |
60 Days Ago | -1.41 | -1.71 | -5.86 | -5.81 |
90 Days Ago | -1.21 | -1.37 | -5.21 | -5.12 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -1.04 | -1.08 | -4.03 | -3.40 |
Zacks Consensus Estimate | -1.16 | -1.30 | -4.68 | -4.47 |
Earnings ESP | 10.78% | 16.92% | 13.85% | 23.94% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.83 | -1.81 | -2.27 | -2.05 | NA |
Estimate | -1.09 | -2.36 | -2.06 | -3.10 | NA |
Difference | 0.26 | 0.55 | -0.21 | 1.05 | 0.41 |
Surprise | 23.85% | 23.31% | -10.19% | 33.87% | 17.71% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more